PT  - JOURNAL ARTICLE
AU  - Isabel Bünger
AU  - Jakob Kreye
AU  - Konstantin Makridis
AU  - Markus Höltje
AU  - Helle Foverskov Rasmussen
AU  - Scott van Hoof
AU  - Tim Ullrich
AU  - Eva Sedlin
AU  - Christian Hoffmann
AU  - Dragomir Milovanovic
AU  - Friedemann Paul
AU  - Jessica Meckies
AU  - Stefan Verlohren
AU  - Wolfgang Henrich
AU  - Rabih Chaoui
AU  - Angela Kaindl
AU  - Harald Prüss
TI  - Synapsin autoantibodies during pregnancy are associated with fetal abnormalities
AID  - 10.1101/2022.09.23.22280284
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.23.22280284
4099  - http://medrxiv.org/content/early/2022/09/25/2022.09.23.22280284.short
4100  - http://medrxiv.org/content/early/2022/09/25/2022.09.23.22280284.full
AB  - Anti-neuronal autoantibodies can be transplacentally transferred during pregnancy and may cause detrimental effects on fetal development. It is unclear whether autoantibodies against synapsin-I, one of the most abundant synaptic proteins, are associated with developmental abnormalities in humans. We prospectively recruited a cohort of 263 pregnant women and detected serum synapsin-I IgG autoantibodies in 13.3%. Seropositivity was strongly associated with abnormalities of fetal development including intrauterine growth retardation. This finding indicates that these autoantibodies may be clinically useful developmental biomarkers and/or even directly participate in the disease process, thus being amenable to antibody-targeting interventional strategies in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the German Research Foundation (DFG) (grants FOR3004, PR1274/4-1, PR1274/5-1, PR1274/9-1), by the Helmholtz Association (HIL-A03), and by the German Federal Ministry of Education and Research (Connect-Generate 01GM1908D) to H.P. The study was supported by the Einstein Stiftung Fellowship through the Guenter Endres Fond and the Sonnenfeld-Stiftung (A.M.K.). DM is supported by the start-up funds from DZNE and the German Research Foundation (SFB MI 2104 and 1286/B10).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Charite Universitaetsmedizin Berlin gave ethical approval for this work (#EA2/220/20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCASPR2contactin-associated protein-like 2CBAcell-based assayELISAEnzymelinked immunosorbent assayHEKHuman embryonic kidneyNMDAN-methyl-DaspartateSYNsynapsinTKOtriple knockout mice